Snowball logo
logo
BVS

Bioventus Inc

BVS โ€ข NASDAQ
$14.26+$0.37ย  (2.66%)
Estimate
P/E
20.1
EPS
0.71
Beta
0.653
Growth
Revenue, YoY
3.76%
Net income, YoY
348.33%
FCF, YoY
7.99%
Forecast
P/E (FWD)
15.7
EPS (FWD)
0.908
About the company
Ticker
BVS
ISIN
US09075A1088
Country
United States of America
Sector (GICS)
Healthcare
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Frequently asked questions

What sector does Bioventus Inc (BVS) operate in?

Bioventus Inc belongs to the Healthcare sector and operates in the Medical Devices industry.

What is Bioventus Inc (BVS) current stock price?

As of the latest data, Bioventus Inc stock price is $14.26, with a previous close of $13.89. Bioventus Inc gained $0.37 in the last trading session, representing a 2.66% increase.

What is Bioventus Inc (BVS) current market capitalization?

Bioventus Inc market cap is approximately 974.03 million.

What is Bioventus Inc (BVS) Earnings Per Share (EPS)?

The trailing EPS is $0.71, and the forward EPS is $0.91.

What is Bioventus Inc (BVS) Price-to-Earnings (P/E) ratio?

Bioventus Inc current P/E ratio is 20.08, with a forward P/E of 15.7.

What is Bioventus Inc (BVS) EBITDA?

Bioventus Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 19.38 million.

Does Bioventus Inc (BVS) pay dividends?

No. Bioventus Inc does not pay a dividend.

How did Bioventus Inc (BVS) perform in its most recent earnings report?

In the last report (June 30, 2026), Bioventus Inc posted an EPS surprise of 0% and a revenue surprise of -1.56%.

What is Bioventus Inc (BVS) beta (volatility) score?

Bioventus Inc has a beta of 0.653, indicating lower volatility than the overall market.